Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes

Juraj Koska, Aramesh Saremi, Scott K. Howell, +5

Diabetes Care

Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes

Juraj Koska, Hertzel C. Gerstein, Paul J. Beisswenger, +1

Diabetes Care

Blood Pressure Variability and Risk of Heart Failure in ACCORD and the VADT

Daniel S. Nuyujukian, Juraj Koska, Gideon Bahn, +2

Diabetes Care

The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study

Juraj Koska, Raymond Q. Migrino, Keith C. Chan, +2

Diabetes Care

Effect of liraglutide on dietary lipid‐induced insulin resistance in humans

Juraj Koska, Lizette Kristine Lopez, Karen D’Souza, +6

Diabetes Obesity and Metabolism

Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT)

Juraj Koska, Daniel S. Nuyujukian, Gideon Bahn, +2

Cardiovascular Diabetology

Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA

Shripad Sinari, Juraj Koska, Yueming Hu, +7

Arteriosclerosis Thrombosis and Vascular Biology

Effects of saxagliptin on adipose tissue inflammation and vascular function in overweight and obese people: a placebo‐controlled study

Juraj Koska, Tracy Osredkar, Karen D’Souza, +5

Diabetic Medicine